Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8190357 | 1.00 | MAOB (0.53) | MAOBKDM1AGRIN1KCNH2TNKS2 | |
| SCHEMBL10477669 | 0.87 | MEN1 (0.50) | MAOBGRIN1MAOATSHRALOX5 | |
| SCHEMBL8481310 | 0.82 | LMNA (0.55) | MAOBKDM1ABCHEMAOANR4A2 | |
| SCHEMBL3004785 | 0.82 | LMNA (0.55) | MAOBKDM1ABCHEMAOANR4A2 | |
| SCHEMBL8483583 | 0.82 | LMNA (0.55) | MAOBKDM1ABCHEMAOANR4A2 | |
| SCHEMBL6583019 | 0.81 | MAOB (0.56) | MAOBKDM1AGRIN1KCNH2TNKS2 | |
| SCHEMBL9967895 | 0.81 | GRM5 (0.48) | MAOBGRIN1MAOATSHRALOX5 | |
| SCHEMBL11633807 | 0.80 | GRIN1 (0.48) | MAOBKDM1AGRIN1KCNH2TNKS2 | |
| SCHEMBL11634144 | 0.80 | GRIN1 (0.48) | MAOBKDM1AGRIN1KCNH2TNKS2 | |
| SCHEMBL27875600 | 0.80 | SPHK1 (0.44) | MAOBKDM1AGRIN1KCNH2TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-6057357-A | USEFUL IN TREATING PAIN, INFLAMMATION, PSORIASIS AND IRRITABLE BOWEL SYNDROME | WARNER-LAMBERT COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1998049158-A1 | PERIPHERALLY SELECTIVE KAPPA OPIOID AGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| US-4146638-A | CARDIOTONIC, VASODILATION, HYPOTENSIVE, ANTIARRYTHMIA AGENTS | BOEHRINGER INGELHEIM GMBH (DE) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | MAOB 290/4885KDM1A 3114/4885GRIN1 1075/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | MAOB 290/4885KDM1A 3114/4885GRIN1 1075/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | MAOB 290/4885KDM1A 3114/4885GRIN1 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.